Contents
Doctors are reaching a clearer consensus: obesity is a complex chronic disease, but body weight and BMI alone cannot show how excess body fat is affecting an individual’s health.
For decades, people living with obesity were often given a deceptively simple message: eat less, exercise more, and try harder.
That advice treated obesity primarily as a matter of personal behavior or willpower. It overlooked the complex biology that regulates hunger, fullness, energy expenditure, fat storage, hormones, and the body’s resistance to weight loss.
Medical understanding is changing.
In a July 1, 2026 National Geographic article titled “Doctors Are Finally Starting to Agree on When Obesity Is a Disease”, health experts described a growing consensus that obesity should be approached as a chronic medical condition rather than a personal failure.
The more difficult question is no longer simply whether obesity can be a disease. It is how clinicians should determine when excess body fat is impairing health and how urgently it should be treated.
That distinction may sound like semantics, but it can affect whether patients receive compassionate care, a thorough medical evaluation, access to treatment, insurance coverage, and appropriate long-term monitoring.
It also explains why laboratory testing is so important.
A scale can measure weight. Body mass index, or BMI, can compare weight with height. Waist measurements can help estimate central adiposity. However, none of these measurements can independently reveal whether excess adipose tissue is affecting blood sugar, cardiovascular risk, liver health, kidney function, inflammation, hormones, or nutritional status.
Laboratory testing helps reveal the part of obesity that cannot be seen.
The American Medical Association formally recognized obesity as a disease in 2013. Since then, major medical organizations have increasingly described obesity as a complex, chronic, and often relapsing condition influenced by biological, genetic, environmental, behavioral, psychological, medication-related, and socioeconomic factors.
The 2026 Obesity Medicine Association Obesity Algorithm emphasizes a comprehensive assessment that considers weight history, potential secondary causes, medications, eating patterns, physical activity, sleep, social and psychological factors, and obesity-related metabolic and mechanical complications.
Adipose tissue is not simply an inactive storage compartment for excess calories. It is biologically active tissue that communicates with the brain, liver, muscles, pancreas, blood vessels, immune system, and reproductive organs.
When adipose tissue becomes excessive, dysfunctional, or concentrated around the abdominal organs, it may contribute to:
Not every person with a larger body develops the same complications. Two people with the same BMI can have very different amounts of visceral fat, muscle mass, insulin sensitivity, liver fat, cardiovascular risk, and organ function.
That is why weight alone cannot provide a complete health assessment.
An international commission published in The Lancet Diabetes & Endocrinology proposed a more precise framework for evaluating obesity.
Under this framework, excess adiposity should first be confirmed through direct body-composition testing or through BMI combined with other measurements, such as waist circumference, waist-to-height ratio, or waist-to-hip ratio.
The framework then separates obesity into two broad categories:
Clinical obesity describes excess adiposity accompanied by evidence that organs, tissues, mobility, or daily physical functioning are already being impaired.
Preclinical obesity describes excess adiposity without current evidence of organ or functional impairment, although the person may have an increased risk of developing disease in the future.
This approach acknowledges that a person can have a high BMI without obvious metabolic impairment, while another person with a lower BMI may carry substantial visceral fat and already show signs of insulin resistance, fatty liver disease, dyslipidemia, or cardiovascular risk.
BMI can therefore remain a useful screening measurement, but it should not be treated as a complete diagnosis.
Calling obesity a disease does not mean that nutrition, physical activity, sleep, stress management, and other behaviors are irrelevant. These behaviors remain important parts of health and treatment.
It means those behaviors occur within a powerful biological system.
The body can respond to weight loss by increasing hunger, altering appetite hormones, reducing energy expenditure, and defending previously established fat stores. Genetics, medications, sleep disorders, endocrine conditions, chronic stress, food access, and environmental influences may further affect body weight and metabolic health.
Recognizing obesity as a disease can help replace blame with medical evaluation.
Instead of asking only, “Why hasn’t this person lost weight?” clinicians can ask more useful questions:
Laboratory testing helps answer many of these questions.
There is no single blood test that diagnoses obesity. Laboratory testing instead helps evaluate obesity’s metabolic effects, detect related diseases, investigate selected contributors, establish a treatment baseline, and monitor progress.
Testing should be individualized according to age, symptoms, medical history, family history, medications, blood pressure, body-fat distribution, reproductive history, and treatment plan.
Obesity, particularly when accompanied by increased abdominal or visceral fat, is strongly associated with insulin resistance.
Insulin resistance occurs when cells in the muscles, liver, and adipose tissue do not respond to insulin as effectively as they should. The pancreas may compensate by producing more insulin, sometimes for years, before fasting glucose reaches the diabetic range.
Tests that may help evaluate blood sugar regulation include:
A1c, fasting plasma glucose, and a two-hour oral glucose tolerance test are established methods for identifying prediabetes and diabetes. Fasting insulin can provide additional metabolic context, but there is no universally accepted fasting-insulin cutoff that independently diagnoses insulin resistance in routine clinical practice.
Testing can identify blood sugar dysregulation before obvious symptoms develop, creating an opportunity for earlier intervention.
Obesity-related metabolic dysfunction may alter how the liver produces, packages, and clears lipoproteins. A person may develop elevated triglycerides, reduced HDL cholesterol, increased atherogenic particle numbers, or other cardiovascular risk patterns.
Tests that may provide useful information include:
Laboratory results should be considered alongside blood pressure, glucose status, kidney function, smoking history, age, family history, medication use, and other cardiovascular risk factors.
The liver is one of the organs most commonly affected by metabolic dysfunction.
Metabolic dysfunction-associated steatotic liver disease, or MASLD, develops when excess fat accumulates in the liver in association with cardiometabolic risk factors. In some people, it may progress from steatosis to inflammation, fibrosis, cirrhosis, and liver-related complications.
Laboratory evaluation may include:
Age, AST, ALT, and platelet count can be used to calculate the FIB-4 score, a noninvasive tool that helps estimate the likelihood of advanced liver fibrosis.
An elevated FIB-4 score does not diagnose fibrosis. It may indicate a need for additional evaluation, such as elastography, imaging, specialized blood testing, or consultation with a healthcare professional.
Normal liver enzymes do not necessarily exclude liver fat or early liver disease. Results should be interpreted together with metabolic risk factors, clinical findings, and imaging when appropriate.
Obesity can affect the kidneys directly and indirectly through diabetes, high blood pressure, inflammation, altered kidney blood flow, and increased filtration demands.
Testing may include:
Kidney abnormalities may remain silent until substantial damage has occurred. Early detection can influence blood-pressure goals, medication selection, diabetes treatment, and cardiovascular risk management.
Hypothyroidism can contribute to fatigue, fluid retention, cold intolerance, constipation, and some weight gain. However, obesity by itself does not prove that a thyroid disorder is present.
Testing may include:
Mild TSH elevations can sometimes occur in association with obesity without representing overt hypothyroidism. Thyroid results therefore require appropriate clinical interpretation.
Testing for cortisol excess, pituitary disorders, or uncommon endocrine causes of weight gain is generally reserved for people with suggestive symptoms, physical findings, or medical histories. Broad endocrine testing is not automatically necessary for everyone with obesity.
Obesity and insulin resistance may influence ovulation, menstrual regularity, fertility, androgen levels, testosterone production, and sexual health.
For women with irregular periods, infertility, acne, excess facial or body hair, or suspected polycystic ovary syndrome, testing may include:
For men with reduced libido, erectile dysfunction, decreased muscle mass, infertility, or persistent fatigue, clinicians may consider:
Hormone testing should be guided by symptoms and medical history rather than body weight alone.
Obesity may be associated with chronic low-grade inflammation, but inflammatory markers are nonspecific. They cannot determine the cause of inflammation on their own.
Selected testing may include:
These tests provide context, but abnormal findings may have causes unrelated to obesity and may require additional evaluation.
A person can have obesity and still have one or more nutritional deficiencies. Calorie excess does not guarantee adequate intake or absorption of vitamins, minerals, protein, or other nutrients.
Nutritional testing may be particularly important for people who:
Depending on the situation, testing may include:
Nutritional monitoring should be tailored to the treatment, symptoms, medical history, and risk of deficiency.
Obesity treatment is increasingly individualized and may include nutritional therapy, physical activity, behavioral support, treatment of sleep disorders, anti-obesity medication, adjustment of contributing medications, or metabolic and bariatric procedures.
Baseline laboratory testing can help identify:
A baseline also creates a reference point for evaluating future changes.
Weight is only one treatment outcome.
A person may experience meaningful health improvements even when weight loss is modest or when the number on the scale temporarily plateaus.
Follow-up laboratory testing may show:
The reverse is also possible. Someone may lose weight while developing nutrient deficiencies, losing excessive lean mass, or experiencing treatment-related complications.
Effective obesity care should therefore assess physical function, symptoms, quality of life, blood pressure, sleep, body composition, metabolic markers, and organ health—not weight alone.
A person with excess adiposity may initially have glucose, cholesterol, liver, and kidney results within standard laboratory reference ranges.
That is encouraging, but it does not guarantee that risk will remain low.
Laboratory results represent a moment in time. They should be considered together with waist size, body composition, blood pressure, family history, age, sleep, medications, reproductive history, physical function, and changes over time.
Someone without current organ dysfunction may fit the emerging concept of preclinical obesity. The goal at that stage is not to shame or label the person. It is to identify risk, preserve organ health, prevent complications, and determine an appropriate level of monitoring and support.
One of the most important consequences of recognizing obesity as a disease is the opportunity to change how patients are treated.
An elevated A1c is not evidence of laziness.
High triglycerides are not a character flaw.
Fatty liver disease is not proof that someone lacks discipline.
These are medical findings that deserve the same careful evaluation, compassion, and evidence-based treatment as abnormalities associated with any other chronic condition.
Obesity care works best when patients and healthcare professionals replace blame with information, identify the factors that can be addressed, and create a sustainable long-term plan.
There is no single testing schedule that is appropriate for everyone.
Testing frequency may depend on:
People with normal baseline findings may need periodic monitoring. Those with abnormal results or active treatment may require testing more frequently.
The purpose is not to order every available laboratory test. It is to select the tests that answer meaningful questions about the individual’s health.
Yes. The American Medical Association and multiple professional medical organizations recognize obesity as a chronic disease. The evolving debate focuses on how to distinguish excess adiposity that is already causing organ or functional impairment from excess adiposity that currently presents primarily as an increased future risk.
BMI is a useful population-level and clinical screening tool, but it does not directly measure body fat, visceral fat, muscle mass, fat distribution, or organ dysfunction. It should be combined with other measurements and a broader health assessment.
A general evaluation may include a glucose test, Hemoglobin A1c, lipid panel, comprehensive metabolic panel, and complete blood count. Thyroid, hormone, nutrient, urine, cardiovascular, or specialized liver tests may be added according to individual risk factors and symptoms.
Yes. Some people with excess adiposity do not currently show measurable metabolic or organ dysfunction. They may still have an increased future risk and may benefit from periodic monitoring and preventive care.
Yes. BMI may miss people who have increased visceral fat, low muscle mass, abnormal fat distribution, or metabolic dysfunction despite a BMI below the traditional obesity threshold.
Not by itself. A fasting insulin test can provide additional context in selected cases, but no universally accepted fasting-insulin cutoff independently diagnoses insulin resistance in routine clinical practice. Established prediabetes and diabetes testing relies primarily on A1c, fasting plasma glucose, and oral glucose tolerance testing.
Laboratory testing is one part of treatment planning. Results may identify complications, safety considerations, and treatment priorities, but decisions should also consider medical history, medications, eating patterns, sleep, physical function, personal goals, treatment access, and professional guidance.
Doctors are reaching a clearer consensus: obesity is not simply a number, a behavior, or a failure of willpower. It is a complex chronic condition that can affect nearly every organ system.
At the same time, not every person with a high BMI has the same disease burden, and not every person with a lower BMI is metabolically healthy.
That is why modern obesity care must look beyond the scale.
Laboratory testing can uncover silent changes in blood sugar, lipids, liver health, kidney function, inflammation, hormones, and nutritional status. It can establish a baseline before treatment, identify complications that require attention, and document health improvements that body weight alone may not show.
The goal is not to reduce a person to a diagnosis or laboratory result. The goal is to replace assumptions with evidence—and use that evidence to support earlier, more personalized, and more compassionate care.
Ulta Lab Tests provides convenient access to laboratory testing that can help individuals better understand their metabolic and overall health. Test selection and results should be reviewed with a qualified healthcare professional, particularly when symptoms are present, results are abnormal, or treatment decisions are being considered.
This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Laboratory results should be interpreted in the context of personal history, symptoms, medications, physical findings, and guidance from a qualified healthcare professional.
These tests help evaluate fasting blood sugar, longer-term glucose exposure, glucose tolerance, and insulin production.
Ulta’s cardiovascular testing pages include conventional lipids and advanced risk markers such as ApoB, Lp(a), and hs-CRP.
These tests assess liver-cell enzymes, bile-duct-associated markers, bilirubin processing, liver protein production, and broader metabolic liver health.
These tests evaluate kidney filtration, urine albumin loss, and electrolyte balance. The combined creatinine-and-cystatin-C test provides an additional filtration estimate, while urine albumin testing can help identify early kidney damage.
Ulta’s thyroid category identifies TSH, Free T4, and thyroid peroxidase antibodies among the core tests used to evaluate thyroid function and possible autoimmune thyroid disease.
These tests may provide additional information when obesity is accompanied by irregular menstrual cycles, infertility, excess androgen symptoms, low libido, erectile dysfunction, or suspected testosterone abnormalities.
The CMP combines markers related to glucose, electrolytes, kidney function, liver-associated measurements, proteins, and calcium, while uric acid testing may be relevant when gout or related metabolic risks are present.
These tests may be especially relevant during restrictive diets, rapid weight loss, medication-assisted weight management, or before and after bariatric procedures.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
